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Abstract
Background: Incisional heia is a frequent complication of midline laparotomy. The use of mesh in hernia repair has
been reported to lead to fewer recurrences compared to primary repair. However, in Ventral Hernia Working Group
(VHWG) Grade 3 hernia patients, whose hernia is potentially contaminated, synthetic mesh is prone to infection.
There is a strong preference for resorbable biological mesh in contaminated fields, since it is more able to resist
infection, and because it is fully resorbed, the chance of a foreign body reaction is reduced. However, when not
crosslinked, biological resorbable mesh products tend to degrade too quickly to facilitate native cellular ingrowth.
Phasix™ Mesh is a biosynthetic mesh with both the biocompatibility and resorbability of a biological mesh and the
mechanical strength of a synthetic mesh. This multi-center single-arm study aims to collect data on safety and
performance of Phasix™ Mesh in Grade 3 hernia patients.
Methods: A total of 85 VHWG Grade 3 hernia patients will be treated with Phasix™ Mesh in 15 sites across Europe.
The primary outcome is Surgical Site Occurrence (SSO) including hematoma, seroma, infection, dehiscence and
fistula formation (requiring intervention) through 3 months. Secondary outcomes include recurrence, infection and
quality of life related outcomes after 24 months. Follow-up visits will be at drain removal (if drains were not placed,
then on discharge or staple removal instead) and in the 1st, 3rd, 6th, 12th, 18th and 24th month after surgery.
Conclusion: Based on evidence from this clinical study Depending on the results this clinical study will yield, Phasix™
Mesh may become a preferred treatment option in VHWG Grade 3 patients.
Trial registration: The trial was registered on March 25, 2016 on clinicaltrials.gov: NCT02720042.
Keywords: Incisional hernia, Complex hernia, Biosynthetic mesh, Mesh repair, Midline laparotomy, Surgical site
occurrence, Complications
* Correspondence: m.vanrooijen@erasmusmc.nl
†M. M. J. van Rooijen and A. P. Jairam contributed equally to this work.
1Erasmus University Medical Centre Rotterdam, Department of Surgery,
Rotterdam, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van Rooijen et al. BMC Surgery          (2018) 18:104 
https://doi.org/10.1186/s12893-018-0439-7
Background
Incisional hernia (IH) is one of the most frequent
complications after midline laparotomy, with inci-
dences varying from 10 to 20%, and even higher
percentages occur in high-risk groups [1, 2]. IH can
lead to a high morbidity and reduces quality of life [3,
4]. Due to the high IH incidence rates, hernia repair
surgery is one of the most frequently performed surgi-
cal procedures [5]. The aim of hernia surgery is to
relieve symptoms, to prevent complications or to
resolve acute complications.
There are several options for hernia repair, including
primary simple suture repair, synthetic or biologic material
placement, repair with relaxing incisions, component
separation and use of musculofascial flaps, utilizing both
open and laparoscopic approaches [6–8]. Synthetic mesh
repair procedures, either open or laparoscopic, lead to
fewer recurrences compared to primary repair; recur-
rences after mesh are 7.7% compared to 23.8% after
primary closure [1, 3, 9, 10]. Improved outcomes are
believed to be related to reduced tension on the fascial
edges and sutures when mesh is used in hernia repair pro-
cedures. Despite reducing hernia recurrence rates, the use
of synthetic mesh has been associated with complications
in approximately 17% of patients. These complications
include infection, pain, adhesions, fistulae and foreign
body reactions including increased inflammation and/or
connective tissue deposition [3, 11]. Especially complex
and large abdominal wall defects continue to pose a chal-
lenge to surgeons, which are associated with recurrence
rates of up to nearly 40% [12].
It can be stated that synthetic mesh is more prone to
infection than primary closure, and this poses a problem
in potentially contaminated hernias like Ventral Hernia
Working Group (VHWG) Grade 3 hernias [13] (Fig. 1).
The success of the mesh repair is jeopardized by potential
contamination due to complicating factors like previous
wound infection, the presence of a stoma or violation of
the gastro-intestinal tract.
The use of a biological tissue matrix has been advo-
cated in (potentially) contaminated hernias, because of
their ability to resist infection, milder inflammatory
response and more orderly collagen deposition than
non-resorbable, synthetic meshes [14–16]. Most often,
biological meshes are derived from human, porcine or
bovine dermis, and these materials have been processed
to acellular sheets of collagen and elastin. The develop-
ment of resorbable mesh products has faced challenges
related to the rate of absorption with complications
arising when the mesh product is resorbed too quickly.
Rapid resorption does not support sufficient healing if
structural reinforcement is diminished during the tissue
repair period.
Therefore, some meshes contain chemicals to induce
additional crosslinking in the graft. This slows down the
degradation process, causing the mesh to retain its
strength for a longer period of time [17]. However,
crosslinking in the mesh reduces its biocompatibility;
causing delayed cellular infiltration and neovasculariza-
tion [17–19]. Ideally, a resorbable mesh should have a
high ability to resist infections and retain its functional
strength for a sufficient period of time to allow native
cellular ingrowth tissue remodeling, maturation of
collagen and gradual shift of mechanical load.
Phasix™ Mesh is a commercially available biosynthetic
mesh. It is a slowly resorbable mesh prepared from
poly-4-hydroxybutrate which has been studied for use as
a biomaterial for different medical applications due its
strength and flexibility, biocompatibility and desirable
degradation times [20–22]. Phasix™ Mesh is comparable
in performance to traditional polypropylene mesh when
using standard measures of mechanical strength (suture
pullout, tear and ball burst strength) [23, 24]. Preclinical
implantation studies indicate that Phasix™ Mesh retains
approximately 70% of its original strength at 12 weeks
[23]. Absorption of the mesh material will be essentially
complete in 12–18months [24]. Given the long-term
strength retention observed in preclinical studies, it is
Fig. 1 Hernia grading system: assessment of risk for surgical site occurrences [13]. (Reprinted from Surgery, 148(3), The Ventral Hernia Working
Group, Incisional ventral hernias: Review of the literature and recommendations regarding the grading and technique of repair, 544-558, Copyright
(2010), with permission from Elsevier)
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anticipated that Phasix™ Mesh may result in low recur-
rence and complication rates with minimal pain and
discomfort when used for hernia repair.
Rationale
From a general perspective, the current literature still is
rather void of evidence-based guidelines regarding
optimal choice of mesh. Simple, uncontaminated hernias
are usually treated with synthetic mesh; biologic meshes
are mostly used in potentially contaminated hernias,
since post-operative mesh infection is anticipated.
Until now, the use of Phasix™ Mesh was studied
primarily in patients up to VHWG Grade 2 [25].
Phasix™ Mesh has been studied prospectively until
now in patients with a clean hernia site (CDC class I
[26]) and up to VHWG Grade 2 [25, 27, 28]. A small
retrospective study has also been conducted, showing
positive results, but not elaborating on the exact
contamination or size of the hernias [29]. Based on the
data that will be gained from this clinical study,
additional evidence may be provided with a view to opti-
mal selection of hernia repair material in a population of
higher risk. Since there is only limited knowledge on the
treatment of VHWG Grade 3 patients, additional infor-
mation is needed on safety and performance of the
Phasix™ Mesh. Based on the combination of the features
of the Phasix™ Mesh proven in previous clinical and
non-clinical investigations, and based on evidence from
the clinical study as described in this protocol, Phasix™
Mesh may become a preferred treatment option in
VHWG Grade 3 patients.
Methods
Objectives
The objective of this study is to collect additional
data on safety and performance of Phasix™ Mesh in
subjects requiring VHWG Grade 3 midline incisional
hernia repair. Among others, Surgical Site Occurrence
(SSO), hernia recurrence, pain, infection, reoperation
and adverse events will be collected for subjects with
a VHWG Grade 3 hernia meeting the study inclusion
and exclusion criteria.
Design
The study has been designed as a post-market,
prospective, single arm, multi-center, open-label study
to collect data on performance and safety of Phasix™
Mesh in subjects with a VHWG Grade 3 midline
hernia. This study will be conducted in 15 hospitals
across Europe, which will each be allowed to include
a maximum of 15 patients.
Participants
Subjects with a VHWG Grade 3 incisional hernia sched-
uled for hernia repair are eligible for this study and will
be asked for informed consent at the outpatient clinic.
VHWG Grade 3 included, among others, previous
wound infection after previous laparotomy (verified in
the patient’s medical record), small bowel resection with
anastomosis, take down of ileostomy with ileocolonic
anastomosis, creation of a stoma, stoma present,
jejunostomy, gastrectomy, and cholecystectomy. Patients
with active infections, infected mesh, abscesses or active
fistulas were not considered among patients with
VHWG Grade 3. Patients solely at risk for an incidental
enterotomy were not included in the population of
which subjects could be drawn from.
Inclusion criteria
All subjects who meet the following criteria listed below
can be enrolled in the study:
– Age 18 years or older
– Diagnosis of an incisional midline hernia
– VHWG Grade 3 hernia
– Size of hernia > 10 cm2, as measured intraoperatively
– Elective retro-rectus hernia repair
– Signed informed consent
Exclusion criteria
All subjects who meet the following criteria must be
excluded from study enrolment:
Regarding the subject:
– Body Mass Index (BMI) > 35 kg/m2
– Peritonitis
– Use or suspected future use of chemotherapeutic
medication during any part of the study
– Known human immunodeficiency virus (HIV)
infection
– Cirrhosis of the liver and/or ascites
– Pregnancy, plans to become pregnant during the
study period or current breastfeeding
– Alcohol/substance abuse problem or a relapse
within 12 months of the screening visit
– Involvement in another interventional clinical study
in the last 30 days prior to informed consent
signature
– Life expectancy of less than 2 years at the time of
enrollment
– Known sensitivity to Phasix™ Mesh or component
materials (subjects with known allergies to
tetracycline hydrochloride or kanamycin sulfate)
– Any condition that, in the opinion of the
investigator, would preclude the use of the study
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device or preclude the subject from completing the
follow-up requirements
Regarding ventral hernia:
– More than 4 previous repairs of the hernia under
observation
– The hernia repair requires more than a single piece
of mesh
– Intact permanent mesh adjacent to the current
hernia to be repaired
Regarding surgery:
– American Society of Anesthesiology class 4 or 5
– Surgical technique requires surgical bridge repair
– Complete removal of existing mesh from a prior
hernia repair (in the same affected area) is not possible
– The hernia repair requires intraabdominal mesh
placement
Study procedures
Screening
Subjects with a diagnosis of incisional midline hernia
requiring surgical repair to close the defect who are
presenting at the study site will be considered potential
subjects for inclusion in this clinical study and should be
pre-screened for study eligibility. If inclusion criteria are
potentially met and no exclusion criteria are anticipated
to be present at the time of pre-screening, the Investiga-
tor will invite the subject to participate in the study.
Informed consent
Subjects will be asked to sign a written informed consent
form. A copy of the informed consent will be provided
to the subject.
Eligibility
Final eligibility will be determined intraoperatively. Subjects
who fail to meet eligibility criteria should be considered
screen failures and will be treated per hospital standard of
care. Reason for screen failure will be documented. Screen
failures are not considered drop-outs, and hospitals will
continue to include patients until the required sample size
has received surgery.
Intervention
All subjects will undergo an open ventral repair of the
hernia. All intraoperative inclusion and exclusion criteria
will be verified.
Subjects will be administered perioperative antibi-
otics according to hospital protocol. Subjects will be
prepared to undergo hernia repair with Phasix™ Mesh.
The general instructions for the use of Phasix™ Mesh
are supplied by the manufacturer.
Surgical technique
The surgical technique will require retro-rectus
placement (onlay is allowed as an exception when
retro-rectus placement cannot be achieved), using
slowly resorbable sutures, with or without Compo-
nent Separation Technique (CST). The peritoneum
should remain posterior to the mesh upon comple-
tion of mesh placement. The mesh may be cut to
shape or size desired for each specific application.
The mesh is to be positioned so its edges extend
beyond the margins of the defect by at least 5 cm. It
is recommended that the mesh is fixated at approxi-
mately 5–6 cm intervals (6–12 absorbable sutures)
around the periphery of the mesh. Defect closure
must be confirmed. All skin incisions will be closed
with staples/sutures and wounds will be dressed with
sterile occlusive dressings.
Outcome parameters
Primary outcome
Primary outcome will be Surgical Site Occurrence (SSO)
up to and including, the 3-month follow-up assessment.
SSOs will be assessed by physical examination at each
study visit through 3months. SSO is defined as
hematoma, seroma, surgical site infection, wound
dehiscence, skin necrosis and fistula, all of which require
intervention.
Secondary outcome
Secondary outcomes will be:
– Surgical Site Occurrence (SSO) after the 3-month
follow-up assessment
– Surgical Site Infection (SSI) [26], is included in
SSOs, but will also be analysed separately
– Hernia Recurrence rate (via physical exam, if
uncertain via ultrasonography, CT or MRI)
– Pain at every follow-up point, measured with the
Visual Analogue Scale (VAS)
– Device related adverse event incidence
– Rate of reoperation due to the index hernia repair
– Quality of Life assessments (Carolinas Comfort
Scale™ [30]1 and EuroQol-5D (EQ-5D) [31])
– Surgical procedure time as measured from incision
to closure (skin to skin)
– Return to work
– Length of hospital stay (day of index surgery until
day of discharge, LOS)
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To measure these outcomes, the following data will be
gathered at different points in time, and saved in an
electronic case report form:
Pre-operative data
– Demographic data (age, sex, race, ethnicity) and
medical history
– Information regarding the inclusion and exclusion
criteria
– Height and weight (calculated to a BMI)
– Length and width of hernia
– Wound assessment
○ signs of infection
○ status and location of potential previous mesh
○ signs of necrosis
– Pain medication usage
– Pain (measured with VAS), discomfort (measured
with Carolinas Comfort Scale™) and quality of life
(measured with EQ-5D)
Peri-operative data
– Information regarding the inclusion and exclusion
criteria
– Intra-operative evaluation of wound and abdomen
– Intra-operative assessment and description of hernia
– Intra-operative assessment of complications, e.g.
enterotomy
– Surgical procedure
– Mesh details
– Fixation details
– Wound closure
Post-operative data
The following data will be collected at fixed follow-up
visits, namely at drain removal (if applicable, otherwise
at discharge or at staple removal), 1 month, 3 months, 6
months, 12 months, 18 months and 24months (Table 1):
– Wound assessment
○ signs of infection
○ status and location of potential previous mesh
○ signs of necrosis
– Hernia recurrence (diagnosed with physical exam, if
uncertain via ultrasonography, or via CT/MRI)
– Adverse events
– Device failure/malfunction/defects
– Pain (measured with VAS)
– Discomfort (measured with Carolinas Comfort Scale™)
– Quality of life (measured with EQ-5D)
In addition, pain medication usage will be collected at
12 and 24months follow-up.
Withdrawal/early termination
A subject is considered an Early Termination if discon-
tinuation occurs after study treatment and before 24
months follow-up. The site will attempt to bring the
subject back to the hospital to complete all Early Ter-
mination visit study procedures: Physical examination,
Pain measured with VAS, Carolinas Comfort Scale™,
EQ-5D and collect adverse events. Reason for subject
discontinuation will be documented when possible.
Sample size consideration
The expected rate of SSO at 3months is 37% based on
historical data (ranging from 21 to 53%) [32–35]. With
75 subjects, the accuracy of the estimated SSO will be
Table 1 Summary of procedures performed per visit
Study procedure Screening and
baseline
Index surgery Drain removal/
discharge
1, 3, 6 and 18 Month
Visit
12 and 24 Month
Visit
Early term
Describe study to potential subject X
Obtain informed consent X
Collect demographics and medical
history
X
Verify eligibility criteria X X
Physical examination X X X X X
Placement of device X
Pain Scale (VAS) X X X X X
Carolinas Comfort Scale™ X X X X
EQ-5D X X X X
Collect Adverse Events X X X X X
Collect pain medications X X
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±11% (i.e. half of the width of the 95% confidence inter-
val of the estimated rate of SSO is 11%). The study plans
to enroll 85 subjects for follow-up. Anticipating on an
attrition rate of about 10% after surgery, 75 subjects will
be evaluable to assess the primary endpoint of Surgical
Site Occurrence (SSO) at 3 months.
Statistical analysis
There will be a modified intention-to-treat population
(mITT), which consists of the subjects in whom Phasix™
Mesh has been implanted. The screen failures were not
implanted, and therefore not used in the analysis. A
per-protocol (PP) population may be created if there are
subjects who have any major protocol deviations. However,
all analyses will be primarily based on the mITT population.
Demographics and baseline characteristics will be
summarized using the mITT population. Summary statis-
tics for categorical variables will include frequency counts
and percentages, and for continuous variables mean,
standard deviation, minimum, median and maximum.
The primary endpoint is the SSO rate up to (includ-
ing) 3 months (± 14 days) post device placement based
on the mITT population. A 95% confidence interval will
be reported for the SSO rate.
The SSO rate after 3 months, the hernia recurrence
rates and surgical site infection rates until 1, 3, 6, 12, 18
and 24 months post device placement will be reported
per visit along with their 95% confidence intervals based
on the mITT population as secondary endpoints. Add-
itionally, Kaplan-Meier analyses for the time from
surgery to hernia recurrence and for the time from
surgery to surgical site infection may be performed.
The secondary endpoints of VAS pain scale, Carolinas
Comfort Scale™ and EQ-5D will be summarized based
on the mITT population with mean, standard deviation,
minimum, median and maximum presented by visit.
Device related adverse events will be tabulated by
system organ class and preferred term. The number of
subjects with a post procedure reoperation due to the
index hernia repair will be presented by time intervals
(until 1, 3, 6, 12, 18 and 24 months post device
placement), surgical procedure duration of the index
procedure (calculated as time of skin closure complete
minus time of first incision) and length of hospital stay
will be summarized descriptively. The time to return to
work will be tabulated using summary statistics as well.
Safety parameters, such as adverse events, device
deficiencies (mechanical failure, malfunction or defects),
physical examination and pain medication, will be sum-
marized using the mITT population.
Subgroup analyses will be performed by sex, sites
(sites with few treated subjects can be combined) and
other factors of interest.
No missing value imputation methods will be applied
in any of the aforementioned analyses.
Safety
In this study, Adverse Events (AE) are defined as any
undesirable clinical event occurring in the abdominal
wall or the abdominal space, as well as any other
undesirable clinical events judged to be related to the
study device or surgical procedure regardless of ana-
tomical region, from time of implantation to end of
study participation. Abnormal laboratory results are
also to be considered as AEs if the results are accom-
panied by clinical signs or symptoms. The investigator
will assess the relationship of an AE to the study
device or procedure and categorize them as ‘definitely’,
‘possibly’ or ‘not related’.
An adverse device effect (ADE) is an AE related to the
use of the mesh product implanted (e.g. insufficient or
inadequate implantation, installation, operation or mal-
function of the Phasix™ Mesh).
Serious adverse events (SAE) are the events that meet
the definition of serious in the ISO 14155:2011.
All events will be followed to satisfactory resolution or
stabilization.
The investigator is responsible for the detection and
documentation of events meeting the criteria and
definition of AE, ADE or SAE. All SAEs and
investigator-judged device related AEs that occur, must
be reported to the sponsor within 24 h of becoming
aware of the event.
An independent safety monitoring committee will
reassess safety of the study protocol and decide about po-
tential adaptations if one of the following criteria are met:
– More than 4 device related SAEs within 3 months of
Phasix™ Mesh implantation
– More than 1 device related recurrence within 3
months of Phasix™ Mesh implantation
The enrolment and treatment of new subjects are sus-
pended until the impact of the study parameters (e.g. surgi-
cal technique, hernia size, mesh size, AE time-course) on
the results is assessed. The follow-up for the subjects
already treated continues.
Monitoring for accuracy and timely submission of data
forms and compliance with the study protocol, meeting
enrolment commitments and applicable regulations will
take place by monitoring personnel.
Ethics
This study will be conducted in accordance with the
principles of the Declaration of Helsinki and Good Clin-
ical Practice guidelines. The Medical Ethical Committee
of the Erasmus Medical Center and the Institutional
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Review Board of every participating hospital have
approved the protocol. Written informed consent
will be obtained from all subjects. All study data will
be recorded in electronic Case Report Forms
provided to the investigational site. Site and subject
numbers will be used to track subject information
throughout the study.
The sponsor of the study has taken out an insurance
policy for all participants of the study, in the case of any
negative consequences experienced due to the study or
the medical device.
The results of the study will be published, regardless
of the outcome, either favourable or unfavourable, in a
peer-reviewed journal and on clinicaltrials.gov, which is
accessible for the public.
Discussion
A major challenge in all hernia studies is the formulation
of a clear definition on the severity or grade of the her-
nia. The difference between grade 3 and 4 hernias is not
always clear, since the classification is more gradual than
it seems. The definition for Grade 3 hernias used in this
study is the same as the one of the Ventral Hernia
Working Group in 2010, which excludes presence of
infected mesh [13].
A discussion topic in this study is the absence of a control
group. No standard treatment is registered for VHWG
Grade 3 hernias. The standard treatment per hospital as a
control group would not suffice, because 15 hospitals in
Europe participate; this would have led to very heteroge-
neously treated control group with very heterogeneous
results, insufficiently valid to compare to the performance
of Phasix™ Mesh. Suture closure was considered as a con-
trol group, but this would have been disadvantageous for
the patient because this has been proven to lead to more
recurrences [1]. Also non-absorbable synthetic mesh was
considered as a control group, because synthetic mesh
placement reduces recurrences compared to suture closure
or closure with the aid of biological mesh [36, 37]. How-
ever, synthetic mesh has been hypothesized to lead to a
high infection rate due to the potential contamination
present in VHWG Grade 3 hernia patients [38, 39]. Thirdly,
the comparison with biological mesh is also hypothesized
to be contra-indicated. Biological mesh has a high salvage
rate when infected [40, 41], but has a higher recurrence rate
than repair with synthetic mesh [37].
Because no standard treatment is recorded for VHWG
Grade 3 hernias, comparing Phasix™ Mesh with synthetic
mesh has been considered to be unethical, since the
potential contamination of the hernia could cause com-
plications when using a synthetic mesh. Comparing
Phasix™ Mesh with just sutures (primary closure) would
not be ethical either, due to the high recurrence rates
associated with primary closure.
It was considered to compare Phasix™ Mesh with the
treating surgeon’s standard of care for VHWG Grade 3
hernias in each participating hospital. However, due to
the lack of consensus on what standard of care for
VHWG Grade 3 hernias is, this would lead to a very
heterogenous control group. This justifies the single-arm
design of the study. Therefore, no randomization or
blinding has been applied, leading to a possible higher
risk of bias. If this study yields positive results, a large
randomized controlled trial would be the next step in
the exploration of Phasix™ Mesh augmentation in
VHWG Grade 3 patients.
Due to the extensive inclusion- and exclusion criteria
used in this study, and the specific goal of assessing
safety and performance, the expected generalizability will
be limited. VHWG Grade 3 patients are very specific
patients with a high risk of developing an SSO. However,
a study has shown that patients with only a history of
infection after previous laparotomy without the other
factors determining VHWG Grade 3, have a lower risk
of developing an SSO. Therefore, it suggests a modified
VHWG Grade 3 scale. It would be useful to analyse the
results of the study described in this protocol between
patients with only a previous infection after a previous
laparotomy, and patients with one or more of the other
factors determining VHWG Grade 3. Stratification for
other confounders or effect modifiers, such as the
presence of a stoma or the CDC wound classification
could be of interest as well.
Surgeon skill is known to be an important predictor in
surgical outcomes. Even though 15 different hospitals
with 16 different surgeons participated, all surgeons have
more than 10 years of experience in hernia surgery.
Conclusion
This multicenter trial will collect additional data on
safety and performance of Phasix™ Mesh in subjects with
a VHWG Grade 3 midline hernia requiring surgical
repair. Based on evidence from this clinical study
Depending on the results this clinical study will yield,
Phasix™ Mesh may become a preferred treatment option
in VHWG Grade 3 patients.
Endnotes
1The CAROLINAS COMFORT SCALE™ questionnaire
was created by and is licensed from the Division of
Gastrointestinal and Minimally Invasive Surgery of
Carolinas Medical Center, North Carolina
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